Vincristine sulfate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1963
- First approval year
- 1963
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Vincristine sulfate
- Molecular weight
- 923.05
- Structure (SMILES)
- CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
- leurocristine sulfate
- Leurocristine sulfate
- marqibo kit
- Marqibo kit
- oncovin
- Oncovin
- vincasar pfs
- Vincasar pfs
- vincrex
- Vincrex
- vincristine sulfate
- Vincristine sulfate
- vincristine sulfate pfs
- Vincristine sulfate pfs
- 22 oxovincaleukoblastine sulfate 1 1 salt who ip
- 22-OXOVINCALEUKOBLASTINE SULFATE (1:1) (SALT) [WHO-IP]
- 37231
- kyocristine
- Kyocristine
- Leurocristine sulfate (1:1) (salt)
- leurocristine sulfate 1 1 salt
- lilly 37231
- LILLY-37231
- marqibo
- Marqibo
- marqibo vincristine sulfate liposomes injection
- novopharm
- Novopharm
- nsc 67574
- NSC-67574
- oncovin
- Oncovin
- vincaleukoblastine 22 oxo sulfate 1 1 salt
- VINCALEUKOBLASTINE, 22-OXO-, SULFATE (1:1) (SALT)
- vincristine sulfate
- Vincristine sulfate
- VINCRISTINE SULFATE [EP MONOGRAPH]
- VINCRISTINE SULFATE [IARC]
- VINCRISTINE SULFATE [JAN]
And 35 more, listed on the interactive page.
- ATC classification codes
- L01CA02
Sources for recorded values
- CAS registry numbers
- 2068-78-2
- ChEMBL ID
- CHEMBL501867
- InChIKey
- AQTQHPDCURKLKT-JKDPCDLQSA-N
- FDA ingredient codes (UNII)
- T5IRO3534A
- 249332
- 5388992
- 138911098
- 11202
- 11203
- Applicant
- LILLY
- Approval date
- 10 Jul 1963
- Application number
- NDA014103
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- vincristine
- Type
- Natural product
- Drug name stem
- vin-
Administration routes
- Parenteral
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P04350
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P07437
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P0DPH7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68363
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68366
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68371
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13509
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13885
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q3ZCM7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q6PEY2
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q71U36
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BQE3
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BUF5
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BVA1
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9H4B7
Open Targets mechanisms
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Rhabdomyosarcoma, Alveolar
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000248
- Subject identifier
- D018232
- Condition
- Astrocytoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Rhabdomyosarcoma, Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000437
- Subject identifier
- D018233
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
And 38 more, listed on the interactive page.
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000211
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001378
- Condition identifier
- EFO_0002918
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003833
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001350
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001365
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001469
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000873
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001023
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001657
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002083
- Highest recorded phase
- 2
And 78 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
- Effect
- misuse
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 110
- Reporting signal score
- 180.395
- Event
- aplastic anaemia
- Reports
- 76
- Reporting signal score
- 146.946
- Event
- blood culture positive
- Reports
- 91
- Reporting signal score
- 225.884
- Event
- bone marrow failure
- Reports
- 192
- Reporting signal score
- 235.839
- Event
- diffuse large b-cell lymphoma
- Reports
- 89
- Reporting signal score
- 175.028
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 92
- Reporting signal score
- 282.242
- Event
- febrile bone marrow aplasia
- Reports
- 176
- Reporting signal score
- 462.287
- Event
- febrile neutropenia
- Reports
- 1,844
- Reporting signal score
- 4,691.74
- Event
- haematotoxicity
- Reports
- 118
- Reporting signal score
- 194.492
- Event
- hepatitis b reactivation
- Reports
- 70
- Reporting signal score
- 150.997
- Event
- hyperbilirubinaemia
- Reports
- 101
- Reporting signal score
- 140.65
- Event
- hypofibrinogenaemia
- Reports
- 53
- Reporting signal score
- 147.399
- Event
- interstitial lung disease
- Reports
- 442
- Reporting signal score
- 644.144
- Event
- mucosal inflammation
- Reports
- 250
- Reporting signal score
- 334.455
- Event
- myelodysplastic syndrome
- Reports
- 139
- Reporting signal score
- 218.576
- Event
- myelosuppression
- Reports
- 128
- Reporting signal score
- 202.127
- Event
- neoplasm progression
- Reports
- 195
- Reporting signal score
- 265.143
- Event
- neoplasm recurrence
- Reports
- 74
- Reporting signal score
- 185.376
- Event
- neuropathy peripheral
- Reports
- 351
- Reporting signal score
- 264.657
- Event
- neutropenia
- Reports
- 739
- Reporting signal score
- 700.478
- Event
- neutropenic sepsis
- Reports
- 93
- Reporting signal score
- 166.864
- Event
- neutrophil count decreased
- Reports
- 225
- Reporting signal score
- 223.803
- Event
- ototoxicity
- Reports
- 60
- Reporting signal score
- 142.858
- Event
- pancytopenia
- Reports
- 373
- Reporting signal score
- 432.948
- Event
- posterior reversible encephalopathy syndrome
- Reports
- 114
- Reporting signal score
- 167.325
And 7 more, listed on the interactive page.
- NCT00000658
- NCT00133302
- NCT00193440
- NCT00323323
- NCT00455897
- NCT00719472
- NCT00972478
- NCT01724021
- NCT02356159
- NCT03571308
- NCT04002947
- NCT04661007
- NCT00001563
- NCT00002524
- NCT00002571
- NCT00022555
- NCT00049036
- NCT00126243
- NCT01775475
- NCT00002093
- NCT00002105
- NCT00002318
- NCT00002462
- NCT00002471
- NCT00002494
And 442 more, listed on the interactive page.
- Dose
- 1.5–2 mg/m2
- Route
- Intravenous
- How often
- Once weekly
- Must be administered via an intact, free-flowing intravenous needle or catheter
- Should be diluted in a flexible plastic container
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 3
- Polar surface area
- 171.17
- Calculated partition coefficient (ALogP)
- 3.52
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 65
- Molecular formula
- C46H58N4O14S
- Monoisotopic mass
- 922.36702371
- Natural product
- Yes
- 61703-309
- Recorded assays
- 4,642
- Active assays
- 1,639
- Confirmatory
- Other
- Screening
- Antineoplastic Agents, Phytogenic
- Tubulin Modulators
Related records
Trials (598)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
- A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
- A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
- A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
- A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
- A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
- A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
- A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
- A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
- A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
- A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
In development for (103)
- Acute leukemia of ambiguous lineage Phase 3
- Acute lymphoblastic leukemia Phase 3
- Acute myeloid leukemia Phase 2
- Adult T-cell leukemia/lymphoma Phase 3
- AIDS Phase 2
- Alveolar rhabdomyosarcoma Phase 3
- Anaplastic large cell lymphoma Phase 2
- Anaplastic oligodendroglioma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 1
- Astrocytoma (excluding glioblastoma) Phase 3
- Autoimmune hemolytic anemia Phase 2
- B-cell acute lymphoblastic leukemia Phase 3
- B-cell chronic lymphocytic leukemia Phase 3
- B-cell non-Hodgkin lymphoma Phase 2
- Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Phase 2
- Brain cancer Phase 1
- Brain neoplasm Phase 3
- Burkitt lymphoma Phase 2
- Carcinoma Phase 3
- Central nervous system cancer Phase 1
Targets (15)
- TUBA1A Tubulin inhibitor
- TUBA1B Tubulin inhibitor
- TUBA1C Tubulin inhibitor
- TUBA3C Tubulin inhibitor
- TUBA3E Tubulin inhibitor
- TUBA4A Tubulin inhibitor
- TUBB Tubulin inhibitor
- TUBB1 Tubulin inhibitor
- TUBB2A Tubulin inhibitor
- TUBB2B Tubulin inhibitor
- TUBB3 Tubulin inhibitor
- TUBB4A Tubulin inhibitor
- TUBB4B Tubulin inhibitor
- TUBB6 Tubulin inhibitor
- TUBB8 Tubulin inhibitor